Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer

Journal of the National Cancer Institute
Yasuhiro TadaChristoph Plass

Abstract

Loss of tumor suppressor CCAAT/enhancer-binding protein-alpha (C/EBPalpha) expression is seen in several human malignancies, including acute myelogenous leukemia and lung cancer. We hypothesized that DNA methylation and histone acetylation of the C/EBPalpha promoter may modulate C/EBPalpha expression in lung cancer. We analyzed C/EBPalpha expression in 15 human lung cancer cell lines and in 122 human lung primary tumors by northern blotting, immunoblotting, and immunohistochemistry. C/EBPalpha promoter methylation was assessed using bisulfite sequencing, combined bisulfite restriction analysis, methylation-specific polymerase chain reaction, and Southern blotting. We examined the acetylation status of histones H3 and H4 at the C/EBPalpha promoter by chromatin immunoprecipitation. Binding of methyl-CpG-binding proteins MeCP2 and MBD2 and upstream stimulatory factor (USF) to the C/EBPalpha promoter was assayed in cell lines that were untreated or treated with histone deacetylase inhibitor trichostatin A and demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) by chromatin immunoprecipitation and by electrophoretic mobility shift assays. DNA methylation and histone acetylation in the upstream region (-1422 to -896) of the C/EBPal...Continue Reading

References

Aug 25, 1995·Science·N D WangG J Darlington
Mar 1, 1995·Molecular and Cellular Biology·N TimchenkoG J Darlington
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·D E ZhangD G Tenen
Dec 10, 1999·Cell·A P Bird, A P Wolffe
Sep 15, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J A van DijckUNKNOWN Working Group on Lung Cancer of the Comprehensive Cancer Centre East
Dec 18, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·R L Momparler, J Ayoub
Mar 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·Daiya Takai, Peter A Jones
Sep 27, 2003·Neoplasia : an International Journal for Oncology Research·Jie LiMing You
Nov 25, 2003·The EMBO Journal·Esteban BallestarManel Esteller
Jan 20, 2004·Molecular and Cellular Biology·Jonathan C ChengPeter A Jones
Apr 30, 2004·Oncogene·Zunyan DaiChristoph Plass
May 4, 2004·Nature Reviews. Cancer·Claus Nerlov
May 28, 2004·Nature·Gerda EggerPeter A Jones
Aug 3, 2004·Genes, Chromosomes & Cancer·Pedro P MedinaMontserrat Sanchez-Cespedes
Sep 3, 2004·Nature Reviews. Cancer·Steven A Belinsky
Nov 25, 2004·Hematology·John C ByrdIan W Flinn
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Han-Shui HsuYi-Ching Wang

❮ Previous
Next ❯

Citations

Dec 24, 2010·JAMA : the Journal of the American Medical Association·Kristi L BennettCharis Eng
Mar 7, 2012·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Shengjie ZhangHongchuan Jin
Oct 23, 2012·Molecular Biology Reports·Ewa BrzeziańskaAdam Antczak
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Shih-Shih ChenChristoph Plass
Nov 17, 2011·Nucleic Acids Research·Javier Rodríguez-UbrevaEsteban Ballestar
Nov 15, 2006·Molecular and Cellular Biology·Tatiana NikitinaChristopher L Woodcock
Jul 9, 2008·Biochemistry. Biokhimii︠a︡·N L Lazarevich, D I Fleishman
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steffen KoschmiederDaniel G Tenen
Jun 22, 2012·PLoS Genetics·Dongning PanYong-Xu Wang
Nov 13, 2010·PloS One·Serena BorrelliRoberto Mantovani
May 19, 2010·Biomarkers in Medicine·Hirendra Nath Banerjee, Mukesh Verma
Apr 2, 2013·Hematology·Sandhya AnnamaneniMohan Reddy Battini
Apr 30, 2015·Japanese Journal of Clinical Oncology·Sailaja KagitaRaghunadharao Digumarti
Mar 31, 2015·Oncogene·W K C Cheung, D X Nguyen
Jan 24, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Daniel B CostaBalazs Halmos
Mar 21, 2007·Cancer Treatment Reviews·Michalis V KaramouzisAthanasios G Papavassiliou
Oct 11, 2013·Nature·Annalisa Di RuscioDaniel G Tenen

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.